odor

[키워드] 1:1 addition Administered All participants allocation sequence ALT anticipated Anticoagulant assigned AST baseline Blinding Blood oxygen saturation C-reactive protein Capsule clinical clinical status Clinical symptoms clinical trial clinical trials CLOCK collected color conducted congenital disorders control group coronavirus COVID-19 creatinine Critically ill CRP Curcumin definitive diagnosis Diseases disorders dissemination double-blind drug Effect Efficacy element eligible patient enteral feeding erythrocyte sedimentation erythrocyte sedimentation rate ESR exclusion criteria Factors female Fever File Hepatic insufficiency hospital ICU ICU patient ICU Patients immune include inclusion criteria independent Inflammatory marker intensive care intensive care unit Intervention intervention group investigators Iran kidney function marker kidney function markers labeling LDH liver male maltodextrin marker matching placebo Medical Sciences Mortality mortality rate normalization number Nurses objective odor outcome oxidative stress oxygen Pancreatitis parameter parenteral nutrition participant Participants Patient PCR test performed physician Physicians piperine Placebo placebo group placebo-controlled Primary outcome protocol provided random randomised randomised controlled trial Randomized Randomized controlled trial Randomly receive recruited Registered registration date registration number registry renal respiratory rate Sample size sealed secondary outcome Secondary outcomes sedimentation rate sensitivity sequence Seven Sex shape status Stratification stratified block randomization study participant Study participants Study protocol supplementary material Support Tablet Taste temperature the placebo group title Trial Trial registration turmeric underlying disease underlying diseases university ventilator Version Warfarin website weight
[DOI] 10.1186/s13063-021-05372-9 PMC 바로가기 [Article Type] Letter